The role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma is a subject of debate. We report a durable complete response in a 62-year-old man Jehovah’s Witness with metastatic clear cell renal cell carcinoma who received two cycles of nivolumab/ipilimumab followed by radical nephrectomy and metastasectomy of known pulmonary disease site, both without a clinical need for perioperative blood transfusions. The patient continues to be without evidence of disease and without additional need for systemic therapy over a year after his radical nephrectomy. The case highlights that cytoreductive nephrectomy continues to play a role in the era of immune checkpoint inhibitors.
CITATION STYLE
Zhuang, T. Z., Harik, L., Force, S., Hadadi, A., Bilen, M. A., Brown, J. T., … Nazha, B. (2022). Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.949400
Mendeley helps you to discover research relevant for your work.